CRA was retained to assess the commercial success of a diabetes drug in combination-use patents as reflected by the manner in which it is used in the marketplace.
CRA conducted market research to understand the competitive landscape, why physicians were prescribing the product, and the product attributes. CRA concluded that the commercial success of the product was not driven unduly by low prices or relatively intensive promotional activity. The list price of the product and the expenditure in detailing activity relative to sales, were comparable to that of its principal competitor.
CRA consultants named top IP strategists in IAM Strategy 300 2021
Robert Goldman, Daniel McGavock, Dr. Richard Razgaitis, and Larry Rosenberg were recognized in the latest edition of IAM Strategy 300 – The World’s Leading IP...